Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | PPM1B | O75688 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887005 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL10165334 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL2500766 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL13560693 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL15057681 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL17816439 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL15590800 | 0.91 | SLC6A2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL596153 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL3944070 | 0.91 | SLC6A2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL4444010 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-119948031-A | Ligand-drug conjugates of isatecan analogs and medical uses thereof | 广州百济神州生物制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-118108734-A | Sesquiterpene lactone derivative and application thereof | 中国人民解放军海军军医大学 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024067811-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE, LTD. (KY) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220235027-A1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2022-07-28 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1392676-B1 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-0973720-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998040344-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CHRM2 199/4885CHRM4 228/4885CHRM3 112/4885 |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | SLC10A1, ERBB3, SLC10A2 | CHRM2 1846/4885CHRM4 1826/4885CHRM3 1142/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CHRM2 199/4885CHRM4 228/4885CHRM3 112/4885 |
| US-20220235027-A1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR3, LPAR2 | CHRM2 650/4885CHRM4 517/4885CHRM3 271/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CHRM2 350/4885CHRM4 322/4885CHRM3 139/4885 |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | LPAR1, LPAR3, LPAR2 | CHRM2 650/4885CHRM4 517/4885CHRM3 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.